Chronic visceral acid sphingomyelinase deficiency
KRAH-nik VIS-er-al AS-id SFEEN-go-MY-eh-lin-ase de-FISH-en-see
Also known as: Niemann-Pick disease type B, Chronic visceral ASMD
At a Glance
What is Chronic visceral acid sphingomyelinase deficiency?
Chronic visceral acid sphingomyelinase deficiency is a rare genetic disorder that affects the body's ability to break down a specific lipid called sphingomyelin. This condition primarily impacts the liver, spleen, and lungs, leading to their enlargement and dysfunction. It is caused by mutations in the SMPD1 gene, which results in deficient activity of the enzyme acid sphingomyelinase. Over time, individuals may experience worsening symptoms such as fatigue, respiratory issues, and abdominal discomfort. Early symptoms often include an enlarged spleen and liver, while later stages can involve lung disease and bone abnormalities. Early diagnosis is crucial to manage symptoms and improve quality of life. The condition can significantly affect family life due to the need for ongoing medical care and monitoring. Prognosis varies, but many individuals can live into adulthood with proper management. Daily life for those affected may involve regular medical appointments, lifestyle adjustments, and potential limitations in physical activities. Support from healthcare providers and family is essential for managing the condition. Research is ongoing to find more effective treatments and improve outcomes for those affected.
Medical Definition
Chronic visceral acid sphingomyelinase deficiency is a lysosomal storage disorder characterized by the accumulation of sphingomyelin in various tissues due to deficient activity of the enzyme acid sphingomyelinase. Histologically, it is marked by the presence of foam cells in affected organs such as the liver, spleen, and lungs. It is classified under Niemann-Pick disease types, specifically type B, which is the non-neuropathic form. Epidemiologically, it is a rare condition with an estimated prevalence of 1 in 250,000 individuals. The disease course is chronic and progressive, with symptoms typically appearing in childhood and worsening over time. Management focuses on symptom relief and supportive care, as there is currently no cure.
Chronic visceral acid sphingomyelinase deficiency Symptoms
Symptoms vary in severity between individuals. Early diagnosis and management can significantly improve outcomes.
Very Common
Hepatosplenomegaly manifests as an enlargement of the liver and spleen, often detected during a physical examination. This enlargement is caused by the accumulation of sphingomyelin due to deficient acid sphingomyelinase activity. Over time, the liver and spleen may continue to enlarge, potentially leading to complications such as portal hypertension. In daily life, patients may experience abdominal discomfort and a feeling of fullness, and regular monitoring and supportive care are essential.
Pulmonary involvement can present as difficulty breathing or reduced exercise tolerance. This occurs due to the accumulation of sphingomyelin in the lungs, leading to interstitial lung disease or emphysema. The condition may progress to significant respiratory impairment over time. Patients may require pulmonary rehabilitation and, in severe cases, supplemental oxygen to manage symptoms.
Fatigue is a persistent feeling of tiredness or exhaustion that is not relieved by rest. It is believed to result from the body's increased metabolic demands and organ dysfunction due to sphingomyelin accumulation. Over time, fatigue can become more pronounced, affecting the patient's ability to perform daily activities. Management includes energy conservation techniques and addressing underlying organ dysfunction.
Common
Thrombocytopenia is characterized by a low platelet count, leading to easy bruising and prolonged bleeding. It is caused by hypersplenism due to splenic enlargement, which sequesters platelets. The condition may worsen as the spleen continues to enlarge. Patients may need to avoid activities that increase bleeding risk and may require platelet transfusions in severe cases.
Growth retardation is observed as a failure to achieve expected growth milestones in children. This is due to chronic illness and nutritional deficiencies associated with organomegaly. Over time, growth may continue to lag behind peers, potentially affecting overall development. Nutritional support and management of underlying disease are crucial to improve growth outcomes.
Hyperlipidemia presents as elevated levels of lipids in the blood, which can be detected through blood tests. It results from altered lipid metabolism due to sphingomyelinase deficiency. If left unmanaged, it can increase the risk of cardiovascular disease over time. Lifestyle modifications and lipid-lowering medications may be needed to manage this condition.
Less Common
Gastrointestinal bleeding may present as blood in the stool or vomit, indicating bleeding in the digestive tract. This can occur due to portal hypertension and varices resulting from liver involvement. If untreated, it can lead to significant blood loss and anemia. Management includes endoscopic interventions and medications to reduce portal pressure.
Bone pain is experienced as persistent discomfort or aching in the bones. It is thought to be related to bone marrow infiltration and altered bone metabolism. The pain may become more severe and frequent over time, impacting mobility and quality of life. Pain management strategies and physical therapy can help alleviate symptoms.
What Causes Chronic visceral acid sphingomyelinase deficiency?
Chronic visceral acid sphingomyelinase deficiency, also known as Niemann-Pick disease type B, is caused by mutations in the SMPD1 gene located on chromosome 11p15.4. The SMPD1 gene encodes the enzyme acid sphingomyelinase, which is responsible for the breakdown of sphingomyelin into ceramide and phosphorylcholine. Mutations in SMPD1 lead to a dysfunctional or deficient enzyme, resulting in the accumulation of sphingomyelin within lysosomes. This accumulation disrupts normal lysosomal function, causing cellular stress and impaired autophagy. As lysosomes fail to degrade sphingomyelin, it leads to the enlargement of these organelles, affecting cellular homeostasis and leading to cell death. The buildup of sphingomyelin and subsequent cell death trigger inflammatory responses, including neuroinflammation and activation of the immune system. This inflammation can contribute to the degeneration of white matter and other structures, particularly in the nervous system. Symptoms appear in a specific pattern due to the differential vulnerability of tissues to sphingomyelin accumulation and inflammation. Organs such as the liver, spleen, and lungs are commonly affected due to their high macrophage content, which are cells that accumulate sphingomyelin. The variability in disease severity among patients is influenced by the specific nature of the SMPD1 mutations, residual enzyme activity, and other genetic or environmental factors. Some patients may experience severe symptoms early in life, while others have milder forms that manifest later. The pattern of organ involvement and symptom progression is also shaped by the extent of immune system activation and the body's ability to manage cellular stress. Overall, the interplay between genetic mutations, cellular dysfunction, and immune responses underlies the pathophysiology of chronic visceral acid sphingomyelinase deficiency.
How is Chronic visceral acid sphingomyelinase deficiency Diagnosed?
Typical age of diagnosis: Chronic visceral acid sphingomyelinase deficiency is typically diagnosed in late childhood or adulthood, often following the presentation of symptoms such as hepatosplenomegaly or pulmonary issues. Diagnosis may be delayed due to the rarity and variability of symptoms. Initial suspicion often arises from clinical evaluation and family history. Early diagnosis is crucial for management and genetic counseling.
The clinician looks for signs such as hepatosplenomegaly, pulmonary symptoms, and growth retardation. A detailed family history is crucial, especially regarding similar symptoms or known genetic disorders. Physical examination may reveal enlarged liver and spleen, and respiratory examination might show reduced breath sounds. This step helps in narrowing down the differential diagnosis and deciding on further investigations.
MRI and CT scans are commonly used imaging modalities. These can reveal organomegaly, particularly of the liver and spleen, and lung involvement such as interstitial changes. Imaging findings support the diagnosis by confirming the presence of characteristic organ changes. They also help exclude other conditions such as Gaucher disease or malignancies.
Specific tests include measuring acid sphingomyelinase activity in leukocytes or fibroblasts. Biomarkers such as chitotriosidase and glycoprotein non-metastatic protein B (GPNMB) are sought. Abnormal results show reduced enzyme activity and elevated biomarkers. These results guide the clinician towards confirming the diagnosis and considering genetic testing.
Sequencing of the SMPD1 gene is performed. Mutations such as missense, nonsense, or frameshift mutations are identified. The presence of pathogenic mutations confirms the diagnosis of chronic visceral acid sphingomyelinase deficiency. Genetic testing results are essential for family counseling and assessing carrier status in relatives.
Chronic visceral acid sphingomyelinase deficiency Treatment Options
Enzyme replacement therapy (ERT) is the main pharmacological approach. It works by supplementing the deficient enzyme, acid sphingomyelinase. Specific drugs like olipudase alfa are used in clinical practice. Clinical trials have shown efficacy in reducing organomegaly and improving pulmonary function. Limitations include infusion reactions and the need for lifelong treatment.
Techniques such as chest physiotherapy and breathing exercises are employed. The goal is to improve pulmonary function and prevent respiratory complications. Sessions are typically conducted several times a week, each lasting about 30 minutes. Measurable outcomes include improved lung capacity and reduced respiratory symptoms. Long-term benefits include enhanced quality of life and reduced hospitalizations.
Indicated for severe hypersplenism or splenic rupture. The procedure involves the surgical removal of the spleen. Expected benefits include improved blood counts and reduced abdominal discomfort. Surgical risks include infection and bleeding, necessitating careful post-operative monitoring. Post-operative care includes vaccinations and prophylactic antibiotics to prevent infections.
The care team typically includes a metabolic specialist, pulmonologist, hepatologist, and genetic counselor. Interventions focus on symptom management, nutritional support, and monitoring of organ function. Psychosocial support strategies involve counseling and support groups for patients and families. Family education is essential for understanding the disease and its management. Long-term monitoring involves regular follow-ups to assess disease progression and treatment efficacy.
When to See a Doctor for Chronic visceral acid sphingomyelinase deficiency
- Severe respiratory distress — indicates potential pulmonary involvement requiring immediate medical attention.
- Acute abdominal pain — could signify splenic or hepatic complications, necessitating urgent evaluation.
- Sudden neurological changes — may suggest central nervous system involvement, which is an emergency.
- Progressive fatigue — may indicate worsening of the condition and should prompt a medical review.
- Persistent cough — could be a sign of pulmonary involvement and warrants further investigation.
- Unexplained weight loss — might suggest disease progression and should be discussed with a healthcare provider.
- Mild abdominal discomfort — monitor for changes and consult a doctor if it worsens.
- Occasional dizziness — track frequency and duration, and seek advice if it becomes more frequent.
Chronic visceral acid sphingomyelinase deficiency — Frequently Asked Questions
Is this condition hereditary?
Chronic visceral acid sphingomyelinase deficiency is inherited in an autosomal recessive pattern. This means both parents must carry a copy of the mutated gene to pass it on to their child. De novo mutations are rare in this condition. Carriers typically do not show symptoms but can pass the gene to offspring. Genetic counseling is recommended for affected families to understand inheritance risks.
What is the life expectancy for someone with this condition?
Life expectancy varies depending on the severity and age of onset. Early diagnosis and management can improve outcomes, while pulmonary and hepatic complications can worsen prognosis. Mortality is often due to respiratory or liver failure. Treatment can enhance quality of life and potentially extend survival. Realistic expectations should include ongoing medical care and monitoring.
How is this condition diagnosed and how long does diagnosis take?
Diagnosis involves clinical evaluation, genetic testing, and enzyme assays. The time from first symptoms to diagnosis can vary, often taking months to years. Specialists such as geneticists and metabolic disorder experts are typically involved. Delays in diagnosis are common due to symptom overlap with other conditions. Confirmation is achieved through genetic testing and enzyme activity measurement.
Are there any new treatments or clinical trials available?
Current research focuses on enzyme replacement therapy and gene therapy. Novel approaches like substrate reduction therapy are also being explored. Clinical trials can be found on ClinicalTrials.gov by searching for 'Niemann-Pick disease type B'. Discuss potential participation with your doctor to understand risks and benefits. New treatments may become available in the next few years, but timelines are uncertain.
How does this condition affect daily life and activities?
Mobility may be affected due to fatigue and organomegaly. Educational accommodations might be necessary for children with the condition. Social and emotional challenges include coping with chronic illness and potential isolation. Family burden can be significant, requiring support and resources. Adaptations such as physical therapy and counseling can help manage daily life.
Learn More
Support & Resources
References
Content generated with support from peer-reviewed literature via PubMed.
- 1.Chronic visceral acid sphingomyelinase deficiency (Niemann-Pick disease type B) in 16 Polish patients: long-term follow-up.
Lipiński P, Kuchar L, Zakharova EY et al. · Orphanet J Rare Dis · 2019 · PMID: 30795770
- 2.Exploring Exhaled Breath Analysis in Adults With Chronic Visceral Acid Sphingomyelinase Deficiency to Identify Potential Biomarkers of Pulmonary Involvement.
Eskes ECB, Schomakers BV, van Weeghel M et al. · J Inherit Metab Dis · 2025 · PMID: 40717061
- 3.Natural disease course of chronic visceral acid sphingomyelinase deficiency in adults: A first step toward treatment criteria.
Eskes ECB, van Dussen L, Brands MMMG et al. · J Inherit Metab Dis · 2025 · PMID: 39177062
- 4.Acid sphingomyelinase deficiency and Gaucher disease in adults: Similarities and differences in two macrophage storage disorders.
Eskes ECB, van Dussen L, Aerts JMFG et al. · JIMD Rep · 2024 · PMID: 39544689
- 5.The value of MR spectroscopy and MR elastography in assessing hepatic involvement of chronic visceral acid sphingomyelinase deficiency in adults.
Eskes ECB, van den Berg-Faaij SAM, Wassenaar NPM et al. · Mol Genet Metab · 2025 · PMID: 40267638
- 6.Combined Emphysema and Interstitial Lung Disease as a Rare Presentation of Pulmonary Involvement in a Patient with Chronic Visceral Acid Sphingomyelinase Deficiency (Niemann-Pick Disease Type B).
Opoka L, Wyrostkiewicz D, Radwan-Rohrenschef P et al. · Am J Case Rep · 2020 · PMID: 32759889
- 7.Case Report of Gastrointestinal Bleeding in an Adult with Chronic Visceral Acid Sphingomyelinase Deficiency.
Cassiman D, Libbrecht L, Meersseman W et al. · Case Rep Gastrointest Med · 2019 · PMID: 31080679
- 8.Glycoprotein non-metastatic protein B (GPNMB) plasma values in patients with chronic visceral acid sphingomyelinase deficiency.
Eskes ECB, van der Lienden MJC, Sjouke B et al. · Mol Genet Metab · 2023 · PMID: 37453187
This content is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.Last reviewed: 2026-06-09